Crossmark

Slow progression of type 1 diabetes associated with pembrolizumab and lenvatinib combination therapy in a patient with probable slowly progressive type 1 diabetes mellitus and endometrial cancer

Crossref DOI link: https://doi.org/10.1007/s13340-024-00771-0

Published Online: 2024-10-29

Published Print: 2025-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hazekawa, Iwaho

Ishii, Norio
License Information

Text and Data Mining valid from 2024-10-29

Version of Record valid from 2024-10-29
More Information

Article History

Received: 18 July 2024

Accepted: 21 October 2024

First Online: 29 October 2024

Declarations

:

: Iwaho Hazekawa and Norio Ishii declare that they have no conflicts of interest.

: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and/or with the Helsinki Declaration of 1964 and later versions.

: Informed consent or substitute for it was obtained from all patients for inclusion in the study.

Document is current

Any future updates will be listed below